Transitioning Technologies from Labs to LDCs
In 2009, 2010, and 2011, Rice 360º hosted a workshop dedicated to advancing the discussion about how to transition health technologies from prototype to wide-scale dissemination in the developing world.
The workshop includes discussions of successful global health technologies in transition, new global health technologies in development, regulatory and ethical concerns associated with disseminating health technologies globally, and a poster session featuring student-designed global health technologies.
Past speakers include:
- John Beale, VillageReach
- Henry Blumberg, Emory University
- Vicki Colvin, Rice University
- Mary Estes, Baylor College of Medicine
- Chloe Feinberg, Ashoka
- Jean Lang, Sanofi Pasteur
- Daniele Latagne, Harvard University
- Aydogan Ozcan, University of CaliforniaundefinedLos Angeles
- Alan Rothman, University of Massachusetts
- Tomasz Tkaczyk, Rice University
- Stanley Schultz, University of Texas Health Science Center at Houston
- Greg Allgood, Procter & Gamble
- Roelie Bottema, Vestergaard Frandsen
- Michael Free, PATH
- Evan Lee, Foundation for Innovative New Diagnostics (FIND)
- Qilin Li, Rice University
- Bob Malkin, Duke University
- John McDevitt, Rice University
- Rachel McKendry, University College London
- Kara Nelson, University of CaliforniaundefinedBerkeley
- Gordon Schutze, Baylor International Pediatric AIDS Initiative
- Sam Sia, Colombia University
- Binseng Wang, International Health Technology Consulting
Palmer Beasley
Keynote speaker, 2011
R. Palmer Beasley, M.D., has become a pioneer for his groundbreaking
work on hepatitis B (HBV) and liver cancer. During his long career as an epidemiologist, he has also worked on everything from HIV/AIDS, rubella, plague and rheumatoid arthritis to diarrhea/ gastroenteritis. Recently, he fought the outbreak of SARS in Taiwan and China. In addition, he organized and led a task force of UT Health Science Center experts to assist the Taiwan government's special Anti-SARS Task Force.
As a faculty member at the University of Washington, Beasley visited Taiwan during a major rubella epidemic and led field trials that established the successful vaccine for rubella, now in worldwide use.
Laboratory findings successfully proved his hypothesis that transmission of the hepatitis B virus occurred between mother and child. It also led to Beasley's suspicion - and eventual proof - that hepatitis B caused liver cancer, one of the leading causes of cancer death in the world. Dr. Beasley has been one of the most vigorous and effective world leaders regarding HBV immunization, convincing the World Health Organization to add HBV vaccine as the seventh vaccine in the global immunization program. His effort to provide immunization against HBV is saving the lives of millions worldwide.
